Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2020-09-30 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-09-30 English
PRIMARY DOCUMENT
Director's Dealing
2020-09-30 English
8-K/A
Board/Management Information Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC, which is a current report used to disclose unscheduled material events or corporate changes. The content focuses on the approval of a new equity incentive plan by stockholders at a special meeting, including voting results and details about the plan. It also includes information about the departure and election of directors or officers. The key section is Item 5.02, which relates to changes in directors or officers, and Item 5.07, which reports voting results. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is primarily an announcement of management and board changes and related stockholder approvals. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (7032 characters) and detailed content support this classification with high confidence.
2020-09-29 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 29, 2020, by Larimar Therapeutics, Inc. It reports on the approval of the 2020 Equity Incentive Plan by stockholders at a Special Meeting, including voting results and details about the plan. The document includes exhibits of the plan and award agreement. The key items reported are related to stockholder voting results and changes in equity incentive plans, which are typical content for an 8-K filing. There is no comprehensive financial data or full financial statements, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy statement itself but references one. The main content is the announcement of voting results at a stockholder meeting. Therefore, the filing type best fitting this document is Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-09-29 English
Regulatory Filings 2020
Regulatory Filings
2020-09-02 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from Larimar Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It is a correspondence related to a securities registration filing, specifically a request for the effective date of a registration statement to be moved up. The document is short (1361 characters) and does not contain financial data, audit information, or detailed report content. It is not a report itself but an administrative filing related to capital raising. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2020-08-31 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.